Portfolio of Diabetes Stocks
Here is a sample of 12 stocks that provide diabetes treatments and monitoring.
| 12 Diabetes Stocks | ||
|---|---|---|
Stock Returns & Price Chart | Symbol | Recent Prices & |
| Abbott Laboratories | ABT | |
| AstraZeneca | AZN | |
| DexCom | DXCM | |
| Eli Lilly | LLY | |
| Insulet Corporation | PODD | |
| Lexicon Pharmaceuticals | LXRX | |
| MannKind Corp. | MNKD | |
| Medtronic | MDT | |
| Novo Nordisk | NVO | |
| Provention Bio | PRVB | |
| Senseonics Holdings | SENS | |
| Tandem Diabetes Care | TNDM | |
| Price data from Quandl as of most recent close. | ||
To inspect the performance of the Diabetes Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.The 10 stocks included in the portfolio computations are: ABT, AZN, DXCM, LLY, PODD, LXRX, MNKD, MDT, NVO and TNDM. The current value of the portfolio assumes that $1,000.00 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. PRVB and SENS were excluded from the portfolio computations because of insufficient price data.
The current value of a $10,000 investment is $17,166. The percent return is 71.66%. The annualized return is 11.41%.
| Return Summary for Diabetes Stocks | |
|---|---|
| Start Date | Aug-29-2014 |
| Start Investment | $10,000.00 |
| End Date | Aug-16-2019 |
| Current Value of Investment | $17,166.40 |
| Total Return | 71.66% |
| Annualized Return | 11.41% |
| Min Date | Nov-30-2016 |
| Min Price | $8,875.78 |
| Max Date | Aug-16-2019 |
| Max Price | $17,166.40 |
| # Values | 61 |
| Number Returns | 1,830 |
| Number Profitable Returns | 1,421 |
| Percent Profitable Returns | 77.65% |
| Number Unprofitable Returns | 409 |
| Percent Unprofitable Returns | 22.35% |
| Profitable to Unprofitable Returns Ratio | 3.47 |
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.